Propan-1-one, 1-(1,2,3,4-tetrahydro-1-quinolyl)-

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: Propan-1-one, 1-(1,2,3,4-tetrahydro-1-quinolyl)-
• 英文别名: 1-(3,4-dihydro-2H-quinolin-1-yl)propan-1-one
• 化学式: C₁₂H₁₅NO
• mdl: MFCD00100042
• 分子量: 189.25
• InChiKey: UASXSFXMEXUTGN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.416
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  Propan-1-one, 1-(1,2,3,4-tetrahydro-1-quinolyl)- 以50%的产率得到
  参考文献：
  名称：

  AHLBRECHT H.; VONDERHEID C., CHEM. BER. , 1975, 108, NO 7, 2300-2311

  摘要：

  DOI：

文献信息

• [EN] RENIN INHIBITORS<br/>[FR] INHIBITEURS DE LA RÉNINE
  申请人：CADILA HEALTHCARE LTD

  公开号：WO2009087649A1

  公开（公告）日：2009-07-16

  The present invention relates to novel renin inhibitors of general formula (1), novel intermediates involved in their synthesis, their pharmaceutically acceptable salts and pharmaceutical compositions containing them. The present invention also relates to a process of preparing compounds of general formula (1), their tautomeric forms, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and novel intermediates involved in their synthesis.

  本发明涉及一般式（1）的新型肾素抑制剂，涉及其合成中所涉及的新型中间体，其药学上可接受的盐以及含有它们的药物组合物。本发明还涉及一种制备一般式（1）化合物的方法，它们的互变异构形式，其药学上可接受的盐，含有它们的药物组合物，以及其合成中所涉及的新型中间体。
• [EN] LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE LA LYSYL OXYDASE-LIKE 2 ET UTILISATIONS DESDITS INHIBITEURS
  申请人：PHARMAKEA INC

  公开号：WO2016144702A1

  公开（公告）日：2016-09-15

  Described herein are compounds that are LOXL2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with LOXL2 activity.

  本文描述了一些LOXL2抑制剂化合物，制备这些化合物的方法，包括这些化合物的药物组合物和药物剂以及在治疗与LOXL2活性相关的疾病、疾病或紊乱的方法。
• Novel Formulations For Opioid-Based Treatments Of Pain Comprising 1-(1,2-Disubstituted Piperidinyl)-4-Substituted Piperazine Derivatives
  申请人：Janssens Frans Eduard

  公开号：US20080070924A1

  公开（公告）日：2008-03-20

  This invention concerns novel formulations for opioid-based treatments of pain and/or nociception comprising opioid analgesics and 1-(1,2-disubstituted piperidinyl)-4-substituted piperazine derivatives having neurokinin antagonistic activity, in particular NK 1 antagonistic activity the use of said formulation for the manufacture of a medicament for the prevention and/or treatment of emesis, pain and/or nociception, in particular in acute and chronic pain treatments, more in particular in inflammatory, post-operative, emergency room (ER), breakthrough, neuropathic and cancer pain treatments and the use of an NK 1 -receptor antagonist for the manufacture of a medicament for the prevention and/or treatment of respiratory depression and tolerance in opioid-based treatments of pain. The pharmaceutical formulations according to the invention comprise NK 1 -antagonists according to the general Formula (I) the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the N-oxide form thereof and prodrugs thereof, wherein all substituents are defined as in claim 1. The pharmaceutical composition according to the invention reduces to a large extent a number of unwanted side-effects associated with opioid analgesics, in particular respiratory depression and tolerance, thereby increasing the total tolerability of said opioids in pain treatment.

  本发明涉及一种新型的阿片类止痛和/或止痛药物治疗的配方，包括阿片类镇痛剂和1-(1,2-二取代哌啶基)-4-取代哌嗪衍生物，具有神经激肽拮抗活性，特别是NK1拮抗活性。所述配方的用途是制造用于预防和/或治疗呕吐、疼痛和/或痛觉的药物，特别是在急性和慢性疼痛治疗中，更特别是在炎症、术后、急诊室、突破性、神经病理性和癌症疼痛治疗中；以及使用NK1受体拮抗剂制造用于预防和/或治疗阿片类止痛药物治疗中的呼吸抑制和耐受性的药物。本发明的制药配方包括一般式(I)的NK1拮抗剂、其药学上可接受的酸或碱盐、其立体化学异构体形式、其N-氧化物形式和其前药，其中所有取代基均如权利要求1所定义。本发明的制药组合物大大减少了与阿片类镇痛剂相关的许多不良副作用，特别是呼吸抑制和耐受性，从而增加了在疼痛治疗中阿片类药物的总耐受性。
• COMPOUNDS FOR MODULATING TRPV3 FUNCTION
  申请人：Chong Jayhong A.

  公开号：US20150299225A1

  公开（公告）日：2015-10-22

  The present application relates to compounds and methods for treating pain and other conditions related to TRPV3.

  本申请涉及化合物和治疗与TRPV3相关的疼痛和其他疾病的方法。
• ACTIVE OXYGEN INHIBITOR
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：EP0513387A1

  公开（公告）日：1992-11-19

  An active oxygen inhibitor which contains an azole derivative represented by general formula (1) or a salt thereof as the active ingredient, wherein R¹ represents phenyl which may be substituted by 1 to 3 lower alkoxy groups or by a lower alkyleneoxy group, etc.; R² represents hydrogen, phenyl, halogen, lower alkoxycarbonyl, lower alkyl, lower aminoalkyl which may be substituted by lower alkyl, dihydrocarbostyrilyl, etc.; R³ represents the group (α), wherein R4B represents hydroxy, carboxy, lower alkenyl or lower alkyl, and m represents 0, 1 or 2; and X represents sulfur or oxygen.

  R²代表氢、苯基、卤素、低级烷氧基羰基、低级烷基、可被低级烷基取代的低级氨基烷基、二氢羧基等；R³代表基团（α），其中 R4B 代表羟基、羧基、低级烯基或低级烷基，m 代表 0、1 或 2；X 代表硫或氧。